Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIGHT-2: Bireociclib + Fulvestrant in HR+/HER2- Advanced Breast Cancer
NCT05077449Phase 3Active, not recruiting
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Nov 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bireociclib in Hormone Receptor-Negative HER2-Positive Breast Cancer (HR-/HER2+), sponsored by Xuanzhu Biopharmaceutical. Started Nov 2021; status: active, not recruiting.
02
Drugs
bireociclib
03
Conditions
Hormone Receptor-Negative HER2-Positive Breast Cancer (HR-/HER2+)
Beyond the preview
Go deeper on NCT05077449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05077449.